Britanny at the Cutting Edge of Science
ManRos Therapeutics was founded in 2007 by Dr. Laurent Meijer (EC Director of Research, CNRS) and Pr. Hervé Galons (EC Professor, Université Paris-Descartes), two leading specialists in cellular and molecular biology and in organic chemistry, respectively. The objectives of ManRos Therapeutics are the identification, characterization, optimization (medicinal chemistry) and preclinical & clinical development of pharmacological kinase inhibitors (some derived from marine natural products) for their use in the treatment of cystic fibrosis, polycystic kidney disease, Down syndrome and Alzheimer’s disease.
An innovative research model
ManRos Therapeutics relies on a dense network of scientific partners, enabling the development of molecules at a reduced cost with the collaboration of the best experts. This explains the diversity of our portfolio, which is uncommon for a biotech of this size.
A unique focus on protein kinases
Dr. Laurent Meijer has dedicated his entire work to selected human disease relevant kinases and their pharmacological inhibitors on which he is one of the leading specialists. This focus through time on a specific field is a considerable strength in the sphere of pharmaceutical research.
Research oriented towards orphan diseases
ManRos Therapeutics focuses its research on disease areas with high unmet medical needs, (cystic fibrosis, polycystic kidney disease, Down syndrome) or against which the existing treatments have limited effects (Alzheimer’s Disease). These pathologies constitute one of the most flourishing sectors of the pharmaceutical industry (reduced regulatory constraints, strong industrial interest, etc.).
A Biotech at the cutting edge of scientific research located in Brittany
ManRos Therapeutics is located in Roscoff, Finistère, Northern Brittany. Thanks to our close linkage to Brittany, we benefit of strong support from many regional actors.
Dr. Philippe de Lavenne
CEO of ManRos Therapeutics and a recognized expert in orphan drugs and new drugs marketing.
Before joining the company, Dr. de Lavenne worked for ten years as Vice-President Europe, Canada, Latin America, Middle East and Africa of Actelion Pharmaceuticals. He heavily contributed to the huge success and large expansion of the company. Prior to Actelion, he worked at Altana-Nycomed, Sanofi, Servier and Ciba-Geigy (Novartis), in many different roles and geographies.
Dr. Laurent Meijer
Co-founder, President and CSO, ManRos Therapeutics
Dr. Laurent Meijer is the co-founder of ManRos Therapeutics and one of the world’s leading experts in disease-relevant kinases and their pharmacological inhibitors. Dr. Meijer has generated more than 40 patents, published over 340 articles, edited 6 books and has been working with three Nobel Prize recipients. In 1985-86, with Edwin Krebs (Nobel Prize award 1992), he extensively characterized the M-phase specific Histone H1 kinase (which turned out to be CDK1/cyclin B). In the late ’80s, with Tim Hunt (Nobel Prize award 2001), he identified the CDK1 associated regulatory subunit as cyclin B. With Paul Greengard (Nobel Prize award 2000), he has been studying brain protein kinases and pharmacological inhibitors for three years (2001-2004) at the Rockefeller University (New York).
Laurent Meijer holds a PhD from University of Lille (1978) and University of Paris (1983). He is married and has two children.
Pr. Hervé Galons
Co-founder, Organic Chemistry
Pr. Hervé Galons is the co-founder of ManRos Therapeutics and a recognized expert in chemical modifications of biological compounds: amino acids, carbohydrates, steroids, and purines.
Apart from his academic work, Pr. Hervé Galons has acquired a strong expertise in drug development, and has been involved in several biotech start-up companies. He is still a Professor of Organic Chemistry at the Université Paris Descartes where he leads a group of researchers in his University laboratory.
Pr. Hervé Galons is a corresponding member of the National French Academy of Pharmacy. He is the author of 150 papers in organic chemistry, co-inventor of more than 10 patents, and author of organic chemistry books. Since 2015, he is the editor-in-chief of the European Journal of Medicinal Chemistry.
Hervé Galons graduated as a pharmacist from the University of Paris, and obtained his PhD in 1976 at Paris-Orsay University. He is the father of two children.